Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.
Barriers are prevalent in less populated areas where treatment options are limited.
Ressources
Original research | 2022
About PWUD, Barriers and enablers, Substitution/OAT
This study examined the perspective of 163 American Indian and Alaska Native people (AIAN) in California to assess culturally based or traditional healing treatment modalities to treat opioid/subst
Original research | 2022
Indigenous, About PWUD, Barriers and enablers
Guidelines | 2021
Clinical guidance, Policy/Regulatory, About prescribers, Illegal drugs, Substitution/OAT, Carries/take-home doses
Guidelines | 2021
Clinical guidance, Policy/Regulatory, About prescribers, Substitution/OAT, Carries/take-home doses, Illegal drugs
Guidelines | 2022
Clinical guidance, Policy/Regulatory, About prescribers, Harm reduction, Safer supply, Carries/take-home doses, Substitution/OAT
Guidelines | 2022
Clinical guidance, Carries/take-home doses, Policy/Regulatory
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19
In March 2020, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued guidance allowing for the expansion of take-home methadone doses.
Original research | 2021
Substitution/OAT, Carries/take-home doses, About PWUD
To limit COVID-19 spread and to avoid disruptions in access to medications for opioid use disorder (MOUD), including buprenorphine and methadone, US federal and state agencies granted unprecedented
Original research | 2022
Carries/take-home doses, About prescribers, About PWUD, Substitution/OAT
Letter | 2022
Overdose, Mortality, About PWUD, Substitution/OAT, Carries/take-home doses
Federal and State Regulatory Changes to Methadone Take-Home Doses: Impact of Sociostructural Factors
We conducted three independent studies on the expanded take-home dose (THD) exemptions to assess implementation and impact on patients and providers in three geographically diverse opioid treatment
Original research | 2022
Substitution/OAT, Carries/take-home doses, Policy/Regulatory, About prescribers, About PWUD, Legal system/law enforcement
The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19
This study aimed to describe changes implemented by programs prescribing pharmaceutical alternatives to the drug supply during the early stages of the COVID-19 pandemic.
Original research | 2022
Safer supply, About prescribers, Transitions in care/treatment
Prevalence and correlates of incarceration following emergency medical services response to overdose
To describe the prevalence of incarceration among survivors of non-fatal overdose addressed through an emergency medical services (EMS) response, and compare incarceration by whether the emergency
Original research | 2022
Overdose, About PWUD, Legal system/law enforcement
This review aimed to evaluate the evidence base supporting the feasibility and clinical effectiveness of all forms of deprescribing initiatives used to discontinue long-term (≥4 weeks) benzodiazepi
Lit review | 2022
Withdrawal, About prescribers, Outcomes, Transitions in care/treatment
Cette étude a permis d’analyser un large éventail de blessures et d’intoxications liées à la consommation de cocaïne seule et en combinaison avec d’autres substances au Canada, à l’aide des données
Recherche | 2022
les stimulants, les hôpitals, la surdose, les drogues illégales
This study examined a wide range of injuries and poisonings related to cocaine only and in combination with other substances in Canada using sentinel surveillance data captured by the electronic Ca
Original research | 2022
Stimulants, Hospitals, Overdose, Illegal drugs
The authors aimed to determine whether flexible take-home buprenorphine/naloxone is as effective as supervised methadone in reducing opioid use in prescription-type opioid consumers with opioid use
Original research | 2022
Substitution/OAT, About PWUD, Outcomes, Carries/take-home doses
We used propensity score (PS) weighting methods to address two methodological questions: (1) Do disparities between sexual minority women (SMW) and heterosexual women persist when differences in ri
Original research | 2022
About PWUD, 2SLGBTQI+, Sex/Gender
We know little about what mitigating effects medications for opioid use disorder (MOUD) offered in jail might have on post-release ED utilization.
Original research | 2022
Hospitals, Legal system/law enforcement, About PWUD, Outcomes
